在核心结合因子急性髓性白血病中,将单剂量gemtuzumab ozogamicin 添加到密集的诱导化疗中
Garrett Bourne1, Kendall Diebold2, Manuel Espinoza-Gutarra2
1Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
在一项回顾性研究中,将gemtuzumab ozogamicin (GO) 添加到核心结合因子急性髓性白血病 (CBF-AML) 的化疗中并没有改善缓解率或生存率. 需要进一步的研究来澄清GO在CBF-AML治疗中的作用.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 核心结合因子急性髓性白血病 (CBF-AML) 的治疗结果各不相同.
- 在一些研究中,gemtuzumab ozogamicin (GO) 已显示出生存益处,但最佳剂量和时间表尚不清楚.
- 对于CBF-AML的强化诱导化疗中GO的作用需要进一步研究.
结论:
- 在CBF-AML中,在诱导过程中单剂量GO并没有提高缓解率或与单独强化化疗法相比的生存益处.
- 年龄和MRD阳性状况被确定为较差结果的风险因素.
- 对CBF-AML患者的现实生存率是有利的,但需要进一步的研究来确定GO在治疗算法中的最佳作用.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
